Short answer
Theravance Biopharma, Inc. (TBPH) filed an 8-K current report with the SEC on September 23, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 3.03 (Material Modification to Rights of Security Holders), Item 5.01 (Changes in Control of Registrant), Item 5.02 (Departure/Election of Directors or Officers), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item 3.01 (Notice of Delisting), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 5.03 (Amendments to Articles of Incorporation or Bylaws). Item 1.01 contains no standalone agreement terms.
- This filing includes Item 3.01, an item that often signal trouble.
Theravance Biopharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Item 1.01 contains no standalone agreement terms
- Material transaction details reside in Items 2.01 and 5.02 of the same filing
Item 2.01 · Completion of Acquisition or Disposition of Assets
- Acquisition completed: TBPH ordinary shares converted into $17.00 cash plus one contingent value right per share
- CVR consideration remains contingent, payable only if specified conditions and timing requirements are met
- Vested and unvested options and equity awards canceled, with eligible holders receiving cash based on $17.00 per share plus CVRs
- Options priced at or above $17.00 received no merger consideration
- Transaction eliminates existing public equity awards and transfers future contingent value to CVR holders
Item 3.01 · Notice of Delisting
- TBPH requested Nasdaq trading suspension at close of September 23, 2026 following transaction closing
- Form 25 filing will delist ordinary shares from Nasdaq, effective 10 days after filing
- Planned Form 15 filing would terminate Exchange Act registration and suspend ongoing SEC reporting obligations
- Shareholders should expect loss of Nasdaq liquidity and reduced public disclosure after deregistration
Item 3.03 · Material Modification to Rights of Security Holders
- Merger completion eliminated existing Ordinary Shareholder rights at the Effective Time
- Shareholders retained only the right to receive the Per Share Merger Consideration
- Event represents a material change in ownership rights tied to the merger transaction
Item 5.01 · Changes in Control of Registrant
- Merger completion triggered a change in control of Theravance Biopharma
- TBPH became a wholly owned subsidiary of Parent, removing standalone public-company status
- Parent funded the transaction with cash on hand and new debt financing
- Transaction details and related governance changes incorporated from Items 2.01, 5.02 and 5.03
Item 5.02 · Departure/Election of Directors or Officers
- Merger-related leadership turnover: Rick Winningham resigned as CEO, alongside six directors
- New three-member board: Kristin Stafford, Scott Platshon and Paul Schneider appointed at closing
- Departures explicitly unrelated to disagreements over operations, policies or practices
- Susannah Gray retained under a 12-month consultation agreement to negotiate a CVR Product License
- Gray’s consultation services carry no compensation from Theravance
Item 5.03 · Amendments to Articles of Incorporation or Bylaws
- Merger-effective governance documents replaced TBPH’s prior charter with the surviving company’s Cayman memorandum and articles
- Corporate name references changed from “Zymeworks Merger Sub 1” to “Theravance Biopharma, Inc.”
- Authorized share capital updated to reflect the merger plan, affecting future corporate and equity authorization
- New indemnification provisions added as required by Section 6.10(b) of the merger agreement
Item 8.01 · Other Events
- Non-tradeable CVRs tied to ampreloxetine monetization, with no equity, voting or dividend rights
- Holders receive pro rata 80% of net proceeds from qualifying transactions within 10 years after merger completion
- First U.S., UK, Spain, France, Germany or Italy commercial sale triggers potential $50 million cash payment
- Holders receive 10% of qualifying net sales through the later of 10 years, patent expiration or loss of exclusivity
- Payments remain highly speculative, dependent on future transactions, approval, commercialization and sales performance
Item EX-99.1 · Exhibit EX-99.1
- Merger consideration includes one nontransferable CVR per ordinary share and eligible equity-award share
- CVRs provide $0.93 per CVR upon first commercial sale in the United States, United Kingdom, Spain, France, Germany or Italy
- Holders receive 80% of net license proceeds from ampreloxetine transactions completed within 10 years after closing
- Holders receive royalties equal to 10% of net ampreloxetine sales during the applicable royalty term
- Equity-award CVRs become ineligible for payments occurring more than five years after closing under Section 409A restrictions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Theravance Biopharma, Inc. 8-K filings
Get the next TBPH 8-K as it lands
Follow TBPH for push alerts, or ask the research agent what this filing means.